Boehringer Ingelheim said it plans to keep up high levels of R&D spending, and could look at China-based companies for dealmaking, as key planks of its strategic approach this year, board chairman Shashank Deshpande said …
Top HHS official makes impassioned pitch to take on China biotech
Senior HHS official and head of Medicare Chris Klomp didn’t mince words when he called competition with China’s ascending biotech industry “a war.” Klomp’s comments,


